product

Our product

The CARMAT artificial heart is a medical device that aims to provide a long-term solution for patients suffering from end-stage heart failure, with no alternative treatment, due to the lack of suitable human organs.

3 KEY INNOVATIONS

  • innovation-1
    Biocompatibility

    The only artificial heart with surfaces in contact with blood that are made of biocompatible materials with the potential to reduce thromboembolic risks.

  • innovation-2
    Pulsatility

    The pump unit hydraulic mimics the two parts of the heartbeat: diastole when the heart muscle relaxes and allows the chambers to fill with blood; systole when the muscle contracts and pumps blood into the arteries.

  • innovation-3
    Auto-regulation

    The first intelligent artificial heart to offer an immediate, automated response to the patient's physiological needs.

The Carmat prosthesis

prothese

THE SYSTEM COMPRISES
THREE PARTS

decran

1. PROSTHESIS

This is the implanted component. It consists of:

  • four biological valves
  • two ventricles, each separated by a membrane into two smaller cavities, one for the blood and one for the actuator fluid
  • a pump assembly comprising two miniature pumps that push the actuator fluid to the membranes and generate the systole and diastole
  • an embedded electronic device to regulate flow based on data measured by the pressure sensors
  • a flexible external bag containing the actuator fluid that expands and contracts to create the heartbeat
  • a percutaneous cable connecting the prosthesis to external components

2. PATIENT MOBILITY KIT

The patient system provides the mobility and autonomy needed to lead a near-normal life. It weighs 3 kg and includes a controller and lithium-ion batteries providing an autonomy of about five hours.

3. HOSPITAL CARE CONSOLE

The medical team must use the hospital console to operate the prosthesis during implantation and track how the device is functioning.

dynamique

Who is it for?

Carmat aims to successfully tackle the problem of heart failure, a major public health challenge and the leading cause of death worldwide. The goal is to offer a long-term solution to treat end-stage heart failure, a disease for which there are currently very few effective treatment options available, most of which rely on a heart transplant.

A new “LEASE OF LIFE” for patients who receive an artificial heart.

A LONG-TERM ALTERNATIVE for the more than 100,000(1) patients suffering from Class IV(2) end-stage heart failure who need a transplant every year.

(1) Rose, Gelijns, Moskowitz, et al. Long-term use of a left ventricular assist device for end-stage heart failure. NEJM. 345:1435-43, 2001. / Rogers, Butler, Lansman, et al. Chronic Mechanical Circulatory Support for Inotrope-Dependent Heart Failure Patients Who Are Not Transplant Candidates: Results of the INTrEPID Trial . J Am Coll Cardiol. 50:741-47, 2007. / Hershberger, Nauman, Walker, et al. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure. J Card Fail. 22:616-24, 2003. / Gorodeski, Chu, Reese, et al. Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure.Circ Heart Fail. 2:320- 24, 2009.

(2) North America Interagency Registry of Mechanically Assisted Circulatory Support : 7 profils de patients, basés sur la gravité clinique